Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (January 2021)
24 slides from Sutro Biopharma's investor presentation, January 2021
Slide 1: Company Overview
Company Overview January 2021 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Sutro Delivering on Best-in-Class Targeted Therapeutics
Sutro Delivering on Best-in-Class Targeted Therapeutics Novel cell-free platform changing the future of oncology Sutro’s platform transforms the cumbersome functional design of complex biologics into a precise and well-controlled process to create homogenous products with differentiated and favorabl
Slide 4: Sutro's Platform Has Enabled Multiple Programs into the Clinic
Sutro’s Platform Has Enabled Multiple Programs into the Clinic One IND per year on average for best-in-class or first-in-class opportunities Potential Future INDs STRO-001 STRO-002 IND for CD74- IND for FolRα- STRO-003 targeting ADC targeting ADC 2018 2019 2020 2021 2022+ Cytokine Derivatives: CC-99
Slide 5: Sutro Wholly-Owned and Partnered Programs
Sutro Wholly-Owned and Partnered Programs Multiple modalities enabled by Sutro’s cell-free platform Program Discovery Preclinical Phase 1/1b Phase 2/3 Commercial Rights STRO-002 FolRα-Targeting ADC Ovarian and Endometrial Cancer STRO-001 Lymphomas: DLBCL, Mantle Cell, Follicular CD74-Targeting ADC M
Slide 6: FolRα-Targeting ADC
STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL
Slide 7: Potential Best-in-Class ADC for Ovarian and Endometrial Cancers
STRO 002 Potential Best-in-Class ADC for Ovarian and Endometrial Cancers STRO-002 is an optimized ADC using precisely positioned non-natural amino acids Novel homogeneous antibody drug conjugate (ADC) using precisely positioned non-natural amino acids FolRα Targets FolRα, which is overexpressed in c
Slide 8: STRO-002 Phase 1 Two-Part Design
STRO 002 STRO-002 GM1 Phase 1 Two-Part Design Dose-escalation has been completed and data was presented December 2020 Part 1: Dose-Escalation Cohort in Ovarian All Patients Baseline Characteristic N=39 All-Comers STRO-002 6.4 mg/kg 61 years Ovarian Cancer Median age (range: 48–79) N=39 STRO-002 3.9
Slide 9: STRO-002 Was Generally Well Tolerated
STRO 002 STRO-002 Was Generally Well Tolerated 86% of TEAEs remain Grade 1-2 and no observed ocular toxicity signal Dose Levels in Dose-Escalation Common TEAEs > 25% By Grade (2) Overall All Patients All Safety Grade 1 Grade 2 Grade 3 Grade 4 Dose Levels (Q3W) (N=39) (N=39) Evaluable Patients N (%)
Slide 10: Tumor Reduction Observed in Majority of Patients
STRO 002 Tumor Reduction Observed in Majority of Patients 10 patients met criteria for response Maximum Change (1) in Tumor Target Lesions 20% Objective RECIST- Response Evaluable 0% per RECIST Population 1.1 (N=31) Responders 10 -30% Partial Response PRu PRu PRu CR (2) 1 PRu Starting Dose, Q3W PR P
Slide 11: Tumor Regression and Control Over Time
STRO 002 Tumor Regression and Control Over Time Deepening of responses over time and others with disease control remaining on study Change in Sum of Diameters for Target Lesions Over Time (N=31) Change from baseline (%) 20 0 Best overall response PD SD PRu -30 PR CR Treatment ongoing as of October 3
Slide 12: Clinical Benefit Seen in Heavily Pre-Treated Patient Population
STRO 002 Clinical Benefit Seen in Heavily Pre-Treated Patient Population Disease control rate of 74% at 12 weeks in RECIST-evaluable population Treatment Duration (1) and Response, Based on Evaluable Patients (N=31) CR Dose Level PR 2.9 mg/kg 3.5 mg/kg CR Individual patients treated with STRO-002 PR
Slide 13: FolRα Expression by Immunohistochemistry
STRO 002 FolRα Expression by Immunohistochemistry (1) In emerging data, responses and anti-tumor activity observed across various FolRα expression levels Individual Patients (N=13) (Ventana FOLR1 assay) 300 Best Overall Response (BOR) H-score 200 PR PRu 100 SD PD 0 FOLR1 PS2+ Score: Weak/Absent Expr
Slide 14: Path Forward for STRO-002 Clinical Development
STRO 002 Path Forward for STRO-002 Clinical Development Next steps for moving towards registration-directed study Part 2: Dose-Expansion Cohorts (Ovarian & Endometrial) First patient for Determine optimal efficacious ovarian cohort dose that is well-tolerated and All-Comers Ovarian Cancer N≈20 STRO-
Slide 15: CD74-Targeting ADC
STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL
Slide 16: Potential First-in-Class Molecule for Patients with NHL and MM
STRO 001 Potential First-in-Class Molecule for Patients with NHL and MM Homogenous ADC with two non-cleavable maytansinoid linker-warheads STRO-001 is a novel homogeneous antibody-drug conjugate (ADC) using precisely positioned non-natural amino acids Comprises two non-cleavable maytansinoid linker-
Slide 17: STRO-001-BCM1 Study Design and Updates
STRO 001 STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose-escalation study with NHL update at ASH 2020 STRO-001-BCM1 Dose-Escalation Study NHL Cohort Update at ASH 2020 Cohort A R/R multiple myeloma RP2D A total of 21 patients have been treated with STRO-001 (N = 30) and 18 patients were
Slide 18: ASH 2020 Update in NHL Cohort
STRO 001 ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) Patients With ≥1 Event, n (%) TEAEs by Grade, Age, median (range), years 64.5 (21–82) Occurring in ≥ 15% Grade 1 Grade 2 Grade 3 Grade 4 Time from diagn
Slide 19: Encouraging Interim Treatment Duration and Responses
Encouraging Interim Treatment Duration and Responses STRO 001 Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Best Doses Demographics Prior Therapies treated with STRO-001 (N=18)(1) PR Response received, level and Diagnosis Individual
Slide 20: Delivering On Our Collaborations
Delivering On Our Collaborations Programs with partners for key franchises BCMA-targeting ADC (CC-99712) Cytokine Derivatives • Dose-escalation study for multiple myeloma began 2H • 1st of 2 programs with lead optimization achieved in 2019 18 months • ~$236M total funding received (1) • ~$103M total
Slide 21: Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer
Deep Arsenal of Tools in the R&D Pipeline Available to Attack Cancer (1) Novel and precise design to drive adaptive and protective immune responses Bispecific Antibody Conjugated Antibody Cytokine Derivative Masked Cytokine Modality Immune Cell Engager ADC or ISAC iADC Bispecific ADC Derivative Targ
Slide 22: Financial Overview
Financial Overview Well-capitalized through cash and other financial sources $202.4M Projected cash runway into of cash, cash equivalents & marketable (1) securities as of Sept 30, 2020 and does not include 2H 2023 , not including potential monetization of ~$135.8M Vaxcyte shares or future BD net pr
Slide 23: Anticipated Value Drivers Through Programs
Anticipated Value Drivers Through Programs Multiple opportunities to impact value into 2021 and beyond Program Indication Milestone Anticipated Timing Updated dose-escalation data 1H 2021 Initial dose-expansion data 2H 2021 STRO-002 Ovarian Cancer Initiate combination study 2H 2021 FolRα ADC EOP1/2
Slide 24: Experienced Leadership Team
Experienced Leadership Team Trevor Hallam, PhD Arturo Molina, Ed Albini Chief Scientific Officer MD, MS, FACP Chief Financial Officer Chief Medical Officer William Newell, JD Chief Executive Officer and Member of the Board of Directors Shabbir Anik, PhD Linda Fitzpatrick Nicki Vasquez, PhD Chief Tec
Sutro Biopharma — Investor Presentation (January 2021) on 6ix